Tanshinone IIA inhibits high glucose‑induced proliferation, migration and vascularization of human retinal endothelial cells

Fan,Keshun; Li,Suyan; Liu,Gaoqin; Yuan,Honghua; Ma,Li; Lu,Peirong

doi:10.3892/mmr.2017.7743

Tanshinone IIA inhibits high glucose‑induced proliferation, migration and vascularization of human retinal endothelial cells

Authors:
- Keshun Fan
- Suyan Li
- Gaoqin Liu
- Honghua Yuan
- Li Ma
- Peirong Lu
View Affiliations

Affiliations: Department of Ophthalmology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Ophthalmology, The First People's Hospital of Xuzhou, Xuzhou, Jiangsu 221002, P.R. China, Research Facility Center for Morphology of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China
Published online on: October 9, 2017 https://doi.org/10.3892/mmr.2017.7743
Pages: 9023-9028

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetic retinopathy is the most universal and severe complication of diabetes mellitus. The primary aim of the present study was to determine whether tanshinone IIA (TSA) has an inhibitory effect on the proliferation, migration and vascularization of human retinal endothelial cells (HREC) under high glucose (HG) conditions and the associated underlying mechanism. It was demonstrated that TSA exhibited a significant inhibitory effect on the proliferation, migration and vascularization of HRECs in a dose‑dependent manner, under conditions of high glucose (25 mM) medium. However, there was no distinct inhibitory effect on HREC proliferation, migration and vascularization under normal glucose (NG, 5.5 mM glucose) conditions. Reverse transcription‑quantitative polymerase chain reaction, western blotting and immunofluorescence experiments were conducted to evaluate the effects of TSA on the expression levels of vascular endothelial growth factor (VEGF) and intercellular adhesion molecule (ICAM)‑1. It was demonstrated that TSA significantly downregulated the expression levels of VEGF and ICAM‑1 in a dose‑dependent manner under HG conditions. Overall, the results of the present study indicate that TSA‑mediated inhibition of proliferation, migration and vascularization in HRECs may be associated with its ability to affect the expression levels of VEGF and ICAM‑1.

View Figures

View References

1	Ginter E and Simko V: Global prevalence and future of diabetes mellitus. Adv Exp Med Biol. 771:35–41. 2012.PubMed/NCBI
2	Willard AL and Herman IM: Vascular complications and diabetes: Current therapies and future challenges. J Ophthalmol. 2012:2095382012. View Article : Google Scholar : PubMed/NCBI
3	Kowluru RA and Chan PS: Oxidative stress and diabetic retinopathy. Exp Diabetes Res. 2007:436032007. View Article : Google Scholar : PubMed/NCBI
4	Witmer AN, Vrensen GF, Van Noorden CJ and Schlingemann RO: Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 22:1–29. 2003. View Article : Google Scholar : PubMed/NCBI
5	Abu E, l-Asrar AM, Nawaz MI, Kangave D, Siddiquei M Mairaj and Geboes K: Angiogenic and vasculogenic factors in the vitreous from patients with proliferative diabetic retinopathy. J Diabetes Res. 2013:5396582013.PubMed/NCBI
6	Kalka C, Masuda H, Takahashi T, Gordon R, Tepper O, Gravereaux E, Pieczek A, Iwaguro H, Hayashi SI, Isner JM and Asahara T: Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res. 86:1198–1202. 2000. View Article : Google Scholar : PubMed/NCBI
7	Li B, Sharpe EE, Maupin AB, Teleron AA, Pyle AL, Carmeliet P and Young PP: VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J. 20:1495–1497. 2006. View Article : Google Scholar : PubMed/NCBI
8	Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 331:1480–1487. 1994. View Article : Google Scholar : PubMed/NCBI
9	Wang X, Wang G and Wang Y: Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 148:883–889. 2009. View Article : Google Scholar : PubMed/NCBI
10	Matsuoka M, Ogata N, Minamino K and Matsumura M: Expression of pigment epithelium-derived factor and vascular endothelial growth factor in fibrovascular membranes from patients with proliferative diabetic retinopathy. Jpn J Ophthalmol. 50:116–120. 2006. View Article : Google Scholar : PubMed/NCBI
11	Abu E, l-Asrar AM, Missotten L and Geboes K: Expression of hypoxia-inducible factor-1alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes. Br J Ophthalmol. 91:822–826. 2007. View Article : Google Scholar : PubMed/NCBI
12	Lim JI, Spee C and Hinton DR: A comparison of hypoxia-inducible factor-α in surgically excised neovascular membranes of patients with diabetes compared with idiopathic epiretinal membranes in nondiabetic patients. Retina. 30:1472–1478. 2010. View Article : Google Scholar : PubMed/NCBI
13	Chung EJ, Kang SJ, Koo JS, Choi YJ, Grossniklaus HE and Koh HJ: Effect of intravitreal bevacizumab on vascular endothelial growth factor expression in patients with proliferative diabetic retinopathy. Yonsei Med J. 52:151–157. 2011. View Article : Google Scholar : PubMed/NCBI
14	Shibuya M: Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 39:469–478. 2006.PubMed/NCBI
15	Hubbard AK and Rothlein R: Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radic Biol Med. 28:1379–1386. 2000. View Article : Google Scholar : PubMed/NCBI
16	Barouch FC, Miyamoto K, Allport JR, Fujita K, Bursell SE, Aiello LP, Luscinskas FW and Adamis AP: Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci. 41:1153–1158. 2000.PubMed/NCBI
17	Zhou L, Zuo Z and Chow MS: Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 45:1345–1359. 2005. View Article : Google Scholar : PubMed/NCBI
18	Gong Z, Huang C, Sheng X, Zhang Y, Li Q, Wang MW, Peng L and Zang YQ: The role of tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antagonism. Endocrinology. 150:104–113. 2009. View Article : Google Scholar : PubMed/NCBI
19	Hwang SL, Yang JH, Jeong YT, Kim YD, Li X, Lu Y, Chang YC, Son KH and Chang HW: Tanshinone IIA improves endoplasmic reticulum stress-induced insulin resistance through AMP-activated protein kinase. Biochem Biophys Res Commun. 430:1246–1252. 2013. View Article : Google Scholar : PubMed/NCBI
20	Zhang Y, Wei L, Sun D, Cao F, Gao H, Zhao L, Du J, Li Y and Wang H: Tanshinone IIA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats. Diabetes Obes Metab. 12:316–322. 2010. View Article : Google Scholar : PubMed/NCBI
21	Li X, Du JR, Yu Y, Bai B and Zheng XY: Tanshinone IIA inhibits smooth muscle proliferation and intimal hyperplasia in the rat carotid balloon-injured model through inhibition of MAPK signaling pathway. J Ethnopharmacol. 129:273–279. 2010. View Article : Google Scholar : PubMed/NCBI
22	Chen Z, Liu G, Xiao Y and Lu P: Adrenomedullin22-52 suppresses high-glucose-induced migration, proliferation, and tube formation of human retinal endothelial cells. Mol Vis. 20:259–269. 2014.PubMed/NCBI
23	Dai C, Liu G, Li L, Xiao Y, Zhang X and Lu P: ADP-ribosylation factor as a novel target for corneal neovascularization regression. Mol Vis. 18:2947–2953. 2012.PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Rajah TT and Grammas P: VEGF and VEGF receptor levels in retinal and brain-derived endothelial cells. Biochem Biophys Res Commun. 293:710–713. 2002. View Article : Google Scholar : PubMed/NCBI
26	Stitt AW, McGoldrick C, Rice-McCaldin A, McCance DR, Glenn JV, Hsu DK, Liu FT, Thorpe SR and Gardiner TA: Impaired retinal angiogenesis in diabetes: Role of advanced glycation end products and galectin-3. Diabetes. 54:785–794. 2005. View Article : Google Scholar : PubMed/NCBI
27	Dagher Z, Park YS, Asnaghi V, Hoehn T, Gerhardinger C and Lorenzi M: Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes. 53:2404–2411. 2004. View Article : Google Scholar : PubMed/NCBI
28	Yuan L, Hu J, Luo Y, Liu Q, Li T, Parish CR, Freeman C, Zhu X, Ma W, Hu X, et al: Upregulation of heparanase in high-glucose-treated endothelial cells promotes endothelial cell migration and proliferation and correlates with Akt and extracellular-signal-regulated kinase phosphorylation. Mol Vis. 18:1684–1695. 2012.PubMed/NCBI
29	Premanand C, Rema M, Sameer MZ, Sujatha M and Balasubramanyam M: Effect of curcumin on proliferation of human retinal endothelial cells under in vitro conditions. Invest Ophthalmol Vis Sci. 47:2179–2184. 2006. View Article : Google Scholar : PubMed/NCBI
30	Shang Q, Xu H and Huang L: Tanshinone IIA: A promising natural cardioprotective agent. Evid Based Complement Alternat Med. 2012:7164592012. View Article : Google Scholar : PubMed/NCBI
31	Jeganathan VS: Anti-angiogenesis drugs in diabetic retinopathy. Curr Pharm Biotechnol. 12:369–372. 2011. View Article : Google Scholar : PubMed/NCBI
32	Kumar B, Gupta SK, Saxena R and Srivastava S: Current trends in the pharmacotherapy of diabetic retinopathy. J Postgrad Med. 58:132–139. 2012. View Article : Google Scholar : PubMed/NCBI
33	Zechmeister-Koss I and Huic M: Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: A systematic review. Br J Ophthalmol. 96:167–178. 2012. View Article : Google Scholar : PubMed/NCBI
34	Titchenell PM and Antonetti DA: Using the past to inform the future: Anti-VEGF therapy as a road map to develop novel therapies for diabetic retinopathy. Diabetes. 62:1808–1815. 2013. View Article : Google Scholar : PubMed/NCBI
35	Stewart MW: Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmol. 7:1257–1267. 2013. View Article : Google Scholar : PubMed/NCBI